Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001223725 | SCV001395884 | uncertain significance | Cerebral creatine deficiency syndrome | 2021-08-27 | criteria provided, single submitter | clinical testing | This sequence change replaces leucine with arginine at codon 116 of the GAMT protein (p.Leu116Arg). The leucine residue is highly conserved and there is a moderate physicochemical difference between leucine and arginine. This variant is present in population databases (rs765281181, ExAC 0.01%). This variant has not been reported in the literature in individuals affected with GAMT-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Natera, |
RCV001833939 | SCV002087036 | uncertain significance | Deficiency of guanidinoacetate methyltransferase | 2021-01-27 | no assertion criteria provided | clinical testing |